-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Coming Soon to a Pharmacy Near You? FXIa Inhibitors and Other Novel Strategies to Prevent or Treat Venous Thromboembolism

Program: Education Program
Session: Thrombosis Prevention and Treatment
Hematology Disease Topics & Pathways:
Clinical Trials, Workforce, Diversity, Equity, and Inclusion (DEI) , drug development, Therapies
Monday, December 12, 2022, 4:30 PM-5:45 PM

Walter Ageno, MD

Medicine and Surgery, University, Varese, Italy

Disclosures: Ageno: Norgine: Membership on an entity's Board of Directors or advisory committees; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees; Viatris: Membership on an entity's Board of Directors or advisory committees; Daiichi Sankyo: Honoraria; BMS-Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bayer: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Leo Pharma: Honoraria, Membership on an entity's Board of Directors or advisory committees.

See more of: Thrombosis Prevention and Treatment
See more of: Education Program
<< Previous Presentation | Next Presentation